Breaking Finance News

Panmure Gordon disclosed ImmuPharma PLC (LON:IMM), maintaining its target price at 100.00GBX today

Yesterday ImmuPharma PLC (LON:IMM) traded 1.08% higher at 37.00GBX. The company’s 50-day moving average is 37.33GBX and its 200-day moving average is 33.53GBX. With the last close up 11.56% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 77,842 shares of IMM changing hands under the typical 127,038

ImmuPharma PLC (LON:IMM) had its stock price target hold steady to 100.00GBX by Panmure Gordon in a report issued Friday September 30, 2016. The updated stock price target implies a possible upside of 1.70% based on the company's last stock close price.

Performance Chart

ImmuPharma PLC (LON:IMM)

With a total market value of 0 GBX, ImmuPharma PLC has with a one year low of 19.10GBX and a one year high of 48.88GBX .

A total of 1 equity analyst has released a ratings update on the stock. zero analysts rating the company a strong buy, 0 brokerages rating the company a buy, zero firms rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a 12-month price target of 100.00GBX.

General Company Details For ImmuPharma PLC (LON:IMM)

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *